Back to top

Research Daily

Wednesday, November 16 2016

Today's Research Daily features new research reports on 16 major stocks, including Biogen (BIIB), Honda (HMC) and Intel (INTC).

Biogen shares have outperformed the broader pharma space, with the stock enthusiastically participating in the post-election rally on hopes of a friendlier regulatory regime under the incoming administration. This tailwind notwithstanding, the analyst likes its strong position in the multiple sclerosis market primarily due to a wide range of products. Cost cutting efforts and MS franchise sales should continue to drive growth. Moreover, the upcoming spin-off of the hemophilia business will allow Biogen to focus on the neurology segment, its key area of expertise. However, the emergence of new PML cases for Tecfidera would weigh heavily on the stock as would pipeline setbacks. Interferon products are also under pressure with patients shifting to oral therapies. (You can read the full research report on Biogen here>>)

Honda shares continued to lag its auto peers, with frequent recalls related to the Takata airbags and the weak Q3 earnings report weighing on the stock. Weak guidance for 2017 and sales problems in the home market are some of the other issues in the Honda story. In the fresh research report issued today, the Zacks analyst discusses the pros & cons of investing in Honda shares. The analyst points out that offsetting the current headwinds, the company has a broad product line-up and expanding operations across Asia. The analyst also likes the company's focus on product and infrastructure development. (You can read the full research report on Honda here>>)

Intel shares have lagged the semiconductor space this year, with the company's weak Q3 results adding to the underperformance. The company beat on the top - and bottom-line in Q3, but guidance came as a disappointment, particularly with respect to margins as well as capex. The market's reaction notwithstanding, the Zacks analyst likes the momentum in the data center group, where macro factors are impacting the enterprise side even as cloud prospects remain strong. Intel’s investments in IoT, security and memory could also pay off this year. (You can read the full research report on Intel here>>)

Other noteworthy reports we are featuring today include CSX Corp. (CSX), Novartis (NVS) and General Growth Properties (GGP).

Free Access: All Zacks Research Reports 
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

ONEOK (OKE) Q3 Earnings Beat Estimates

The Zacks analyst believes that ONEOK Inc.'s proactive approach to reduce capital spending and operating costs will strengthen its financial health and boost performance

New Upgrades

New Downgrades